Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM4003 + Pembrolizumab in Advanced NSCLC and Solid Tumors
NCT04866485Phase 1Unknown
- Sponsor
- Harbour BioMed
- Start
- Jun 2021
- Primary completion
- Feb 2023
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of porustobart in non-small cell lung cancer (NSCLC) and solid tumor, sponsored by Harbour BioMed. Primary endpoints: Dose-Limiting Toxicity at 21 days and Objective Response Rate at 2 years. Status: unknown.
02
Drugs
porustobart
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT04866485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866485.